Leukemia & Lymphoma最新文献_第5页

Are we maintaining minimal residual disease in myeloma? 我们是否在骨髓瘤中维持最小残留病变？

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-21 DOI: 10.1080/10428194.2025.2455485

Mohammed A Aljama, Hasib M Sidiqi, Morie A Gertz

引用次数: 0

Indolent lymphoma: addressing the needs of survivors. 惰性淋巴瘤：解决幸存者的需求。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-28 DOI: 10.1080/10428194.2025.2456970

Pasquale L Fedele, Stephen Opat

{"title":"Indolent lymphoma: addressing the needs of survivors.","authors":"Pasquale L Fedele, Stephen Opat","doi":"10.1080/10428194.2025.2456970","DOIUrl":"10.1080/10428194.2025.2456970","url":null,"abstract":"Over the past two decades, there has been a continuous improvement in outcome for patients with indolent lymphoma (iNHL) resulting in a gradual accumulation of survivors. While life expectancy in the current era approaches that of the lymphoma-free population, patients continue to experience lifelong complications of the disease and its treatment affecting general health, emotional, psychological and social wellbeing, relationships, employment, finances, and fitness. Contemporary care models while suited to the management of lymphoma are often lacking when it comes to identification and management of these additional needs. Given improvements in physical survival achieved over the past decades, it is timely for us to focus on other issues affecting patient wellbeing including immunodeficiency and infection, second cancers, cardiovascular disease, bone health, psychological wellbeing, and sexual health. Many of these aspects are in the domain of the primary care physician; however, there is limited guidance on how these issues should be addressed. It is now time for us to engage our patients, their caregivers, and other healthcare providers in care aspects beyond the lymphoma diagnosis, so they can anticipate a rich and full life, free from both direct and indirect consequences of the lymphoma diagnosis.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1021-1035"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. GMALL-PH-01试验的最终分析：标准化疗联合达沙替尼一线治疗费城染色体阳性急性淋巴细胞白血病的II期研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-08 DOI: 10.1080/10428194.2025.2460737

Fabian Lang, Andreas Voss, Guido Kobbe, Christian Junghanss, Joachim Beck, Andreas Viardot, Knut Wendelin, Jens Panse, Lisa Heberling, Vladan Vucinic, Boris Böll, Max Topp, Dieter Hoelzer, Hubert Serve, Nicola Goekbuget, Oliver G Ottmann, Heike Pfeifer

{"title":"Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.","authors":"Fabian Lang, Andreas Voss, Guido Kobbe, Christian Junghanss, Joachim Beck, Andreas Viardot, Knut Wendelin, Jens Panse, Lisa Heberling, Vladan Vucinic, Boris Böll, Max Topp, Dieter Hoelzer, Hubert Serve, Nicola Goekbuget, Oliver G Ottmann, Heike Pfeifer","doi":"10.1080/10428194.2025.2460737","DOIUrl":"10.1080/10428194.2025.2460737","url":null,"abstract":"Imatinib (IMA) plus chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) is established treatment for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). We investigated the use of dasatinib (DASA) combined with intensive chemotherapy in ALL (18-55 years) first-line in a prospective, multicenter phase II trial by the GMALL study group. 140 mg DASA QD was used with a pediatric-based induction and consolidation chemotherapy according to GMALL 07/2003 protocol with recommended consecutive HCT. Nineteen of 20 planned patients were enrolled in 12 centers. The hematologic CR rate after induction was 79% with an overall MRD negativity rate of 62.5%. Six patients died during induction and two discontinued therapy. This regimen achieved deep molecular responses but was associated with a higher than expected early mortality (21%) and was stopped prematurely due to toxicities. The GMALL therefore adopted a combination of low intensity chemotherapy plus IMA as its current induction regimen.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1079-1087"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutations and higher mutation burden in myeloproliferative CMML compared to myelodysplastic CMML. 慢性髓单细胞白血病临床、病理和分子特征的综合分析：与骨髓增生异常CMML相比，骨髓增生性CMML中ASXL1和NRAS突变频繁，突变负担更高。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-17 DOI: 10.1080/10428194.2025.2453093

Yoonseo Jeong

引用次数: 0

Polatuzumab vedotin extravasation injury: a case report. Polatuzumab vedotin外溢性损伤1例报告。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-25 DOI: 10.1080/10428194.2025.2456092

Sushila A Toulmin, Hana I Nazir, Jeremy S Abramson, Jacob D Soumerai, Esther E Freeman

引用次数: 0

Aleukemic soft-tissue relapse post allogeneic hematopoietic cell transplantation in T-prolymphocytic leukemia. 同种异体造血细胞移植治疗t前淋巴细胞白血病后白血病软组织复发。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-08 DOI: 10.1080/10428194.2025.2462950

Colin J Thomas, David Porter, Vivianna M Van Deerlin, Siddharth Bhattacharyya, Veronica Carvajal, Joseph Kim, Salvatore Priore, Guang Yang, James N Gerson, Stefan K Barta

引用次数: 0

Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement. 同种异体造血干细胞移植并发KMT2A::MLLT1重排的成人急性髓系白血病患者分离的中枢神经系统B淋巴/髓系胆管复发。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-10 DOI: 10.1080/10428194.2025.2460046

Yao Sun, Na Liu, Yingjie Liu, Jing Deng, Jiang Du, Liangding Hu

引用次数: 0

(CAR-)T cell dynamics following chimeric antigen receptor T cells for large B cell lymphoma: a translational tale. （CAR-）T细胞动力学跟随嵌合抗原受体T细胞治疗大B细胞淋巴瘤：一个翻译故事

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-13 DOI: 10.1080/10428194.2025.2456096

M Gambella, S Carlomagno, A M Raiola, S Sivori, E Angelucci

{"title":"(CAR-)T cell dynamics following chimeric antigen receptor T cells for large B cell lymphoma: a translational tale.","authors":"M Gambella, S Carlomagno, A M Raiola, S Sivori, E Angelucci","doi":"10.1080/10428194.2025.2456096","DOIUrl":"10.1080/10428194.2025.2456096","url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough in the treatment of B-cell malignancies. CAR-T cells infusion generally follows a chemotherapy regimen whose lymphodepleting properties create a favorable environment for the expansion of engineered T cells. While this process appears straightforward, emerging evidence reveals that complex mechanisms, collectively representing immune dynamics following CAR-T cell infusion, influence CAR-T cells behavior. In advance of infusion, a final-product enriched with less stressed CAR-T cells can improve their expansion and persistence, providing a biological rationale for early apheresis and administration. Following infusion, the emergence of dysfunctional CAR-T subpopulations, like regulatory or NK-like CAR-T cells, can impair efficacy. The recovery of non-CAR transduced T cells adds further complexity, as these cells could either impact outcomes or exacerbate complications, such as infections or prolonged cytopenia. In this review, we summarize the latest advances in understanding the immune dynamics following CAR-T cell infusion for large B-cell lymphomas, with a focus on both CAR-engineered and native T cell populations, and their impact on treatment efficacy and patient outcomes.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1036-1044"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. 成人b细胞急性淋巴细胞白血病的一线免疫治疗联合策略：降低化疗强度和毒性，提高疗效。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-10 DOI: 10.1080/10428194.2025.2449582

Jayastu Senapati, Hagop Kantarjian, Diane Habib, Fadi G Haddad, Nitin Jain, Nicholas J Short, Elias Jabbour

{"title":"Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.","authors":"Jayastu Senapati, Hagop Kantarjian, Diane Habib, Fadi G Haddad, Nitin Jain, Nicholas J Short, Elias Jabbour","doi":"10.1080/10428194.2025.2449582","DOIUrl":"10.1080/10428194.2025.2449582","url":null,"abstract":"Using immunotherapeutic agents like inotuzumab ozogamicin (InO), blinatumomab, or chimeric antigen receptor T (CAR T)-cell therapy in frontline adult B-cell acute lymphoblastic leukemia (B-ALL) therapy is promising. These agents are mostly well tolerated and have different toxicity profiles than conventional chemotherapy, enabling their combination with chemotherapy. Additionally, they have often been shown to overcome the traditional adverse ALL risk features. Recently blinatumomab was approved as part of consolidation therapy in MRD negative B-ALL; however, a significant proportion of patients had progressed or relapsed before reaching the timepoint of blinatumomab administration. Including InO/blinatumomab from induction onwards could induce earlier and deeper remissions. Modifications of dosing and administration schedules, as with the fractionated InO schedule with low-intensity chemotherapy, and subcutaneous blinatumomab, appear to reduce the toxicity and improve the anti-ALL efficacy. CAR T-cell therapies like brexucabtagene autoleucel as a consolidation approach have shown positive outcomes. The feasibility of using CAR T-cells to reduce the need for long-drawn maintenance and the need for allogeneic hematopoietic stem cell transplantation (HSCT) are questions of ongoing clinical trials. Newer generation CAR T-cell products like obecabtagene autoleucel appear as effective and safer. Better disease monitoring through next generation sequencing based measurable residual disease analysis could identify patients where treatment intensification including HSCT, or deintensification, is suitable.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"989-1000"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia. 新一代测序确定的微小残留疾病的存在并不是急性淋巴细胞白血病儿童预后的可靠生物标志物。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-22 DOI: 10.1080/10428194.2025.2456100

Elizabeta Krstevska Bozhinovikj, Nadica Matevska-Geshkovska, Marija Staninova Stojovska, Emilija Gjorgievska, Aleksandra Jovanovska, Nevenka Ridova, Irina Panovska Stavridis, Svetlana Kocheva, Aleksandar Dimovski

{"title":"Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia.","authors":"Elizabeta Krstevska Bozhinovikj, Nadica Matevska-Geshkovska, Marija Staninova Stojovska, Emilija Gjorgievska, Aleksandra Jovanovska, Nevenka Ridova, Irina Panovska Stavridis, Svetlana Kocheva, Aleksandar Dimovski","doi":"10.1080/10428194.2025.2456100","DOIUrl":"10.1080/10428194.2025.2456100","url":null,"abstract":"The role of next-generation sequencing (NGS) for minimal residual disease (MRD) assessment in pediatric acute lymphoblastic leukemia (ALL) is still under consideration. Fifty pediatric patients were prospectively evaluated for specific clonal rearrangements of immunoglobulin and T-cell receptor genes using NGS analysis at diagnosis and on days 33 and 78 from therapy onset. The prognostic value or the NGS-MRD status was analyzed after a median follow-up of 4 years. All but one patient with negative NGS-MRD status on day 33 are in clinical remission. A total of 29 (58%) patients were NGS-MRD positive on day 33, of which 9 (18%) patients remained positive on day 78. However, only a small percentage of the patients with positive NGS-MRD status on day 33 and day 78 relapsed: 21% (6/29) and 33% (3/9), respectively. Positive NGS-MRD status is not a reliable prognostic biomarker in children with ALL and warrants careful consideration in disease stratification.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1121-1128"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0